News Column

Researchers from Memorial Sloan-Kettering Cancer Center Discuss Findings in Therapeutics (Axitinib sensitization of high Single Dose Radiotherapy)

August 6, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Therapeutics. According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "Single Dose Radiation Therapy (SDRT) provides remarkably high rates of control even for tumors resistant to fractionated radiotherapy. SORT tumor control depends on acute acid sphin-gomyelinase-mediated endothelial cell injury and monoclonal antibodies targeting Vascular Endothelial Cell Growth Factor (VEGF) signaling radiosensitized tumor endothelium when delivered immediately prior to irradiation."

Our news editors obtained a quote from the research from Memorial Sloan-Kettering Cancer Center, "Here we evaluate the ability of the oral VEGF receptor inhibitor, axitinib, to sensitize tumor endothelium and increase tumor control with SDRT. Axitinib was added to primary cultured endothelial cells, or administered orally to Sv129/BL6 mice bearing radiosensitive. MCA/129 sarcoma or radioresistant B16F1 melanoma flank tumors, followed by SDRT. Endothelial apoptosis was assessed by TUNEL assay or bis-benzamide staining. Mice with irradiated tumors were followed for 90 days to evaluate the impact of axitinib on SDRT tumor control. Pre-treatment with axitinib increased acute endothelial cell apoptosis following SDRT in vitro, and in vivo for both MCA/129 and B16F1 tumors. Axitinib correspondingly increased SORT tumor growth delay and complete response rate (by 40%) for both tumors. Administration precisely 1 h before SDRT was critical for radiosensitization."

According to the news editors, the research concluded: "Axitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT."

For more information on this research see: Axitinib sensitization of high Single Dose Radiotherapy. Radiotherapy and Oncology, 2014;111(1):88-93. Radiotherapy and Oncology can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Radiotherapy and Oncology - www.elsevier.com/wps/product/cws_home/506042)

The news editors report that additional information may be obtained by contacting S.S. Rao, Mem Sloan Kettering Canc Center, Lab Signal Transduct, New York, NY 10021, United States. Additional authors for this research include C. Thompson, J. Cheng, A. Haimovitz-Friedman, S.N. Powell, Z. Fuks and R.N. Kolesnick (see also Therapeutics).

Keywords for this news article include: Angiology, Endothelium, Radiotherapy, Therapeutics, New York City, United States, Endothelial Cells, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters